MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer
Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneum...
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CAPVAXIVE Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease.
Britain defends investment record as Merck scraps labs over pharma environment
Britain defended its record on attracting investment on Thursday after U.S. drugmaker Merck said it was abandoning a new London research centre and a top industry lobby group warned a challenging b...
Merck axes £1bn London lab in blow to UK life sciences
Britain's ambition to become a global science powerhouse has suffered a major setback after Merck, known in Europe as MSD, abandoned plans for a £1 billion research hub in London. About 125 scienti...
Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?
MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.
Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Merck & Co., Inc. (NYSE:MRK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Robert Davis - Chairman, President & CEO Eliav Barr - Chief ...
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia i...
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C in Phase 3.
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025.
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on hug...
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Caroline A. Litchfield - Executive VP & CFO Dean Y.
Merck to Lay Off Workers and Narrows Guidance as Earnings Fall
Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, as it looks to redirect resources toward new product launches.
Related Companies